Finch Therapeutics Group, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense
Stock-based compensation expense
Impairment of in-process research and development
Impairment of goodwill
Loss on loan extinguishment
Impairment of long-lived assets
Gain on lease termination
(Gain) loss on sale and disposal of property and equipment
Non-cash operating lease and interest cost
Benefit for deferred income taxes
Other non-cash operating lease cost
Changes in operating assets and liabilities:
Accounts receivable
Due from related party
Prepaid expenses and other current assets
Other non-current assets
Accounts payable
Accrued expenses and other current liabilities
Other non-current liabilities
Due to related party
Deferred revenue
Deferred rent
Operating lease liabilities
Net cash used in operating activities
CASH FLOWS PROVIDED BY (USED IN) INVESTING ACTIVITIES:
Proceeds on sale of property and equipment
Purchases of property and equipment
Net cash provided by (used in) investing activities
CASH FLOWS (USED IN) PROVIDED BY FINANCING ACTIVITIES:
Proceeds from exercise of stock options and issuance of common stock under employee stock purchase plan, net
Proceeds from PPP Loan
Proceeds from borrowings under loan agreement, net
Repayment of loan
Payment of loan prepayment and termination fee
Proceeds from initial public offering, net of underwriting discounts, commissions and offering costs
Proceeds from issuance of Series D convertible preferred stock
Payment of Series D redeemable convertible preferred stock issuance costs
Proceeds from underwriters' exercise of overallotment option, net of underwriting discounts and commissions and initial public offering costs
Principal payments on finance lease obligation
Payment of deferred offering costs
Net cash (used in) provided by financing activities
NET CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH
Cash, cash equivalents and restricted cash at beginning of year
Cash, cash equivalents and restricted cash at end of year
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid for interest
Cash paid in connection with operating lease liabilities
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Property and equipment in accounts payable and accrued liabilities
Remeasurement of right-of-use asset
Right-of-use assets obtained in exchange for new operating lease liabilities
Prepaid rent reclassified to right-of-use assets
Prepaid rent reclassified to operating lease liability
Right-of-use assets and operating lease liability reduced for lease termination
Conversion of redeemable convertible preferred stock into common stock
Operating right-of-use assets obtained in exchange for new operating leases upon adoption of ASC 842
Deferred initial public offering costs in AP and accruals

Comments